

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US05/003754

International filing date: 04 February 2005 (04.02.2005)

Document type: Certified copy of priority document

Document details: Country/Office: US
Number: 60/542,371
Filing date: 06 February 2004 (06.02.2004)

Date of receipt at the International Bureau: 09 May 2005 (09.05.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

1314580

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

April 27, 2005

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: 60/542,371

FILING DATE: *February 06, 2004*

RELATED PCT APPLICATION NUMBER: *PCT/US05/03754*



Certified by

Under Secretary of Commerce
for Intellectual Property
and Director of the United States
Patent and Trademark Office

PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR §1.53(c).

U.S. PTO
60/542371
020604

| INVENTOR(S) | | | | | |
|---|--|---------------------------|--|---|--|
| Given Name (first and middle [if any]) | | Family Name or Surname | | Residence (City and either State or Foreign Country) | |
| Peter J. | | Wettstein | | Rochester, MN | |
| Mike | | Strausbauch | | Rochester, MN | |
| Heather | | Hardin | | Rochester, MN | |
| Nancy | | Borson | | Rochester, MN | |
| Additional inventors are being named on the <u>0</u> separately numbered sheets attached hereto | | | | | |
| TITLE OF THE INVENTION (500 characters max) | | | | | |
| Complexed Peptide and Adjuvant for Improved Vaccines | | | | | |
| CORRESPONDENCE ADDRESS | | | | | |
| Direct all correspondence to: | | | | | |
| <input checked="" type="checkbox"/> Customer Number: <u>26191</u> | | | | | |
| OR | | | | | |
| <input type="checkbox"/> Firm or Individual Name | | | | | |
| Address | | | | | |
| Address | | | | | |
| City | | State | | ZIP | |
| Country | | United States | | Telephone | |
| | | | | Fax | |
| ENCLOSED APPLICATION PARTS (check all that apply) | | | | | |
| <input checked="" type="checkbox"/> Specification | | Number of Pages <u>30</u> | | <input type="checkbox"/> CD(s), Number <u></u> | |
| <input checked="" type="checkbox"/> Drawing(s) | | Number of Sheets <u>9</u> | | <input checked="" type="checkbox"/> Other (specify) <u>acknowledgement postcard</u> | |
| <input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76. | | | | | |
| METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT | | | | | |
| <input checked="" type="checkbox"/> Applicant Claims small entity status. See 37 CFR 1.27. | | | | FILING FEE | |
| <input checked="" type="checkbox"/> A check or money order is enclosed to cover the filing fees. | | | | AMOUNT (\$) | |
| <input type="checkbox"/> The Director is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number: <u>06-1050</u> | | | | <u>\$80</u> | |
| <input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached. | | | | | |
| The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government. | | | | | |
| <input type="checkbox"/> No. | | | | | |
| <input checked="" type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are: <u>AI-16052</u> <u>The National Institutes of Health</u> | | | | | |

Respectfully submitted,

Signature Allyson Hatton

Date February 6, 2004

Typed Name Allyson R. Hatton, Ph.D., Reg. No. 54,154

Telephone No. (617) 542-5070

Docket No. 07039-501P01

20801635.doc

CERTIFICATE OF MAILING BY EXPRESS MAIL

Express Mail Label No. EL 964 758 230 US

Date of Deposit February 6, 2004

PROVISIONAL APPLICATION FOR PATENT

under

37 CFR §1.53(c)

TITLE: COMPLEXED PEPTIDE AND ADJUVANT FOR
IMPROVED VACCINES

APPLICANT: PETER J. WETTSTEIN, MIKE STRAUSBAUCH, HEATHER
HARDIN AND NANCY BORSON

CERTIFICATE OF MAILING BY EXPRESS MAIL

Express Mail Label No. EL 964 758 230 US

February 6, 2004
Date of Deposit

Complexed Polypeptide and Adjuvant for Improved Vaccines

GOVERNMENT SUPPORT

The work described herein was carried out, at least in part, using funds from the U.S. government under grant number AI-16052 awarded by THE NATIONAL INSTITUTES OF HEALTH. The government may therefore have certain rights in the invention.

TECHNICAL FIELD

This invention relates generally to the field of immunotherapy, and more particularly to enhanced immunogenic polypeptides.

BACKGROUND

Tumor-specific cytotoxic T-lymphocytes (CTLs) have been a principal focus for immunotherapy because of their exquisite specificity in lysing tumor cells with limited collateral damage. The objective of such immunotherapy is the priming for expansion of CTLs that are specific for tumor-specific polypeptides.

Proteins encoded by genes mapping to the major histocompatibility complex (MHC) present short polypeptides to cytotoxic and helper T cells. These short polypeptides provide the stimulus for activation and expansion of specific T cells. There has been a major focus on using these immunogenic polypeptides to vaccinate individuals for protection against infectious agents and tumors. The principal focus has been on polypeptides that are presented by MHC class I molecules to cytotoxic T lymphocytes (CTLs). In the case of human cancers, these polypeptides are usually injected in an oil emulsion along with cytokines and adjuvants. Importantly, the polypeptides that are used are generally of lengths that optimally bind to MHC class I molecules.

SUMMARY

The invention is based, at least in part, on the discovery that a short, strongly immunogenic polypeptide can efficiently complex with and precipitate a CpG molecule. Attachment of the strongly immunogenic polypeptide to a more weakly immunogenic polypeptide can precipitate and focus the CpG adjuvant to increase *in vivo* priming of a cytotoxic T-lymphocyte (CTL) response, and thus increase the immunogenicity of the more weakly immunogenic polypeptide. The strongly immunogenic polypeptide (referred to herein as a

immunogenic polypeptide. The strongly immunogenic polypeptide (referred to herein as a “CpG-interacting amino acid sequence”) can include at least one cysteine (Cys) residue and at least one positively charged amino acid residue, and the CpG molecule can include at least one sulfur atom, such as linked by a phosphorothioate diester linkage. Accordingly, the invention provides compositions, including a bipartite immunogenic polypeptide that includes a CpG-interacting amino acid sequence fused to a CTL-activating amino acid sequence that can be heterologous to the CpG-interacting amino acid sequence. Also provided are methods of identifying and using a CpG-interacting amino acid sequence and a bipartite immunogenic polypeptide, such as for enhanced immunogenicity.

In one aspect, a composition containing a polypeptide and a CpG molecule is provided. The polypeptide can include (1) an amino acid sequence that can activate a cytotoxic T lymphocyte (CTL) (referred to herein as a “CTL-activating sequence”), and (2) a CpG-interacting amino acid sequence that is heterologous to the CTL-activating sequence. The CpG-interacting amino acid sequence can include at least one cysteine residue and at least one positively charged amino acid residue, and the CpG molecule can include at least one sulfur atom. The CpG-interacting amino acid sequence can include no more than about 15 (*e.g.*, 12, 10, 8, or 6) amino acid residues, and the amino acid sequence can include a B-X-B sequence, where B is a positively charged amino acid residue and X is an amino acid residue. The residue can be, for example, an arginine or lysine. In one embodiment, the CpG-interacting amino acid sequence can be B-X-B-X-B, B-X-X-B-X-B, B-X-X-B-X-X-B, and the like. Furthermore, the amino acid sequence can include at least one cysteine residue and at least one (*e.g.*, 2, 3, 4 or more) positively charged amino acid residues. For example, the positively charged amino acid residues can flank the Cys residue. In one embodiment, the CpG-interacting amino acid sequence includes the sequence KCSRNR (SEQ ID NO:1).

In one embodiment, the CTL-activating amino acid sequence is not longer than about 50, amino acid residues (*e.g.*, about 25, 20, 15, or 10 amino acids, or less), and in another embodiment the entire polypeptide (CTL-activating sequence + CpG-interacting amino acid sequence) is less than 50 amino acid residues (*e.g.*, about 40, 35, 30, 25, or 20 amino acids, or less) in length.

In one embodiment, the CpG molecule of a composition has a phosphorothioate backbone.

Also provided herein are methods for producing a composition that has enhanced immunogenicity. One exemplary method includes (a) obtaining a polypeptide that has a CTL-activating sequence and a CpG-interacting amino acid sequence, and (b) contacting the polypeptide to a CpG molecule containing a sulfur atom. The CTL-activating amino acid sequence can be heterologous to the CpG-interacting amino acid sequence, and the CpG-interacting amino acid sequence can include at least one cysteine residue and at least one positively charged amino acid residue.

Also provided is a solution, such as an aqueous solution, that contains a precipitate. A “precipitate,” as referred to herein, is a solid material visible by the naked eye or by light microscopy. A precipitate of a solution can contain a polypeptide, and a CpG molecule. As described above, the polypeptide can include a CTL-activating sequence and a CpG-interacting amino acid sequence. The CpG-interacting amino acid sequence can include at least one cysteine residue and at least one positively charged amino acid, and the CpG molecule can include a sulfur atom.

The methods provided herein also include a method for making a solution. One such method includes obtaining a polypeptide having a CTL-activating sequence and a CpG-interacting amino acid sequence, and contacting the polypeptide to a CpG molecule containing at least one sulfur atom. The contacting step can be performed in a solution, such as an aqueous solution, and under conditions favorable for precipitate formation between the polypeptide and the CpG molecule. The CTL-activating sequence can be heterologous to the CpG-interacting amino acid sequence, and the CpG-interacting amino acid sequence can include at least one cysteine residue and at least one positively charged amino acid residue.

Methods for activating cytotoxic T lymphocytes are also provided. For example, one method for activating cytotoxic T lymphocytes in a mammal includes administering a composition having a polypeptide and a CpG molecule to a mammal. As described above, the polypeptide can include a CTL-activating sequence and a CpG-interacting amino acid sequence that is heterologous to the CTL-activating sequence. The CpG-interacting amino acid sequence can include at least one cysteine residue and at least one positively charged amino acid residue, and the CpG molecule can include at least one sulfur atom.

Screening methods are also provided. One such screening method includes a means of identifying a polypeptide that activates cytotoxic T lymphocytes. The method includes

(a) combining a test polypeptide with a CpG molecule to form a mixture; (b) administering the mixture to a mammal, such as a mouse or a rat; (c) harvesting cytotoxic T lymphocytes from the mammal, such as from the spleen or lymph nodes of the mammal; and (d) determining whether or not the level of CD8⁺ cytotoxic T lymphocytes in the mammal is increased compared to the level of CD8⁺ cytotoxic T lymphocytes in the mammal before step (b). An increase in the level of CD8⁺ cytotoxic T lymphocytes indicates that the test polypeptide can activate cytotoxic T lymphocytes.

Another screening method can be used to identify a CpG-interacting amino acid sequence. According to one such method, a test amino acid sequence is contacted (*e.g.*, in solution) with a CpG molecule, and it is determined whether or not the test amino acid sequence and the CpG molecule can form a precipitate. The formation of a precipitate can indicate that the test amino acid sequence is a CpG-interacting amino acid sequence. The determination step can be performed, for example, by direct visualization, such as by looking for the formation of a precipitate in the solution. The determination step can also be performed by measuring the absorbance of the solution, such as comparing absorbance of the solution before and after the contacting step.

Also provided are methods for identifying a CpG-interacting amino acid sequence. In one embodiment, the method includes (a) administering a polypeptide/CpG molecule mixture to a mammal, and (b) determining whether or not the mixture activates CTLs from the mammal to a level greater than the level of activation that occurs in a control mammal that received a control polypeptide/CpG molecule mixture. The polypeptide of the polypeptide/CpG molecule mixture can include a CTL-activating amino acid sequence and a test amino acid sequence; the polypeptide of the control polypeptide/CpG molecule mixture will lack the test amino acid sequence. Determining that the level of CTL activation is greater in the presence of the test amino acid sequence is an indication that the sequence is a CpG-interacting amino acid sequence. The determining step can include an immunocytochemical technique, such as an ELISA or ELISPOT assay.

One feature of the invention is a composition comprising a CpG molecule and a polypeptide containing more than about four cysteines (and more than about two disulfide bonds) within a sequence of about 100 contiguous amino acids. The polypeptide can be an antigenic polypeptide, such as a synthetic or a natural antigenic polypeptide. As used herein, a

“natural polypeptide” contains an amino acid sequence that is found *in vivo*, such as in a mammal (*e.g.*, a human).

There are many advantages to delivering a polypeptide (*e.g.*, a polypeptide having a CpG-interacting amino acid sequence and a CTL-activating sequence) and CpG molecules together in the form of a therapeutic regimen or vaccine. Delivery of the two molecules in one immunotherapeutic composition simplifies vaccination, and in addition, can provide each component protection from degradation and facilitate transport of the components into the cell. The relative ease of producing the vaccines described herein can reduce the time required to develop a vaccine to months or weeks or even days. The relative ease can also facilitate the custom design of vaccines for individual tumor types, or particular pathogenic diseases, for timely application.

Sequestering the CpG molecule in a complex can also prevent the development of toxic, systemic responses that are frequently observed when free synthetic CpG molecules are administered. Without wishing to be bound by theory, the complexes may provide for a “timed-release” of smaller units composed of antigen and CpG.

In another advantage, the complexing phenomenon can be used for targeting small molecules for intracellular delivery, such as for gene therapy applications.

The development of effective, polypeptide-based vaccines for a number of different types of human cancers has been pursued in order to take advantage of the selective expression of specific polypeptides in those tumors. These efforts have principally focused on the use of polypeptides with lengths that are optimal for direct presentation to effector T lymphocytes. The compositions described herein, including the vaccine polypeptides described herein can be optimized specifically for *in vivo* priming through consideration of the mechanisms that regulate presentation of polypeptides by professional antigen presenting cells (APCs) to effector T cells.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, useful methods and materials are described below. The materials, methods, and examples are illustrative only and not intended to be limiting. Other features and advantages of the invention will be apparent from the accompanying drawings and description, and from the claims. The contents of all references,

pending patent applications and published patents, cited throughout this application are hereby expressly incorporated by reference. In case of conflict, the present specification, including definitions, will control.

DESCRIPTION OF DRAWINGS

FIG. 1 is an example of primary ELISPOT assay results. B6 female mice were primed sub cu with 100 μ g polypeptide +10 μ g MPL-AF + 100 μ g CpG. After 10 days, spleens were removed and CD8⁺ CTLs were purified and mixed with RMA-S cells pulsed with the HY2, HY1, or H60 polypeptides in a primary ELISPOT assay. The wells shown include 4 x 10⁵ CD8⁺ CTLs as responders. The graph indicates frequency of activated CD8⁺ T cells in response to polypeptide stimulation.

FIG. 2 is a comparison of two mixtures: (1) 100 μ g of CpG + 100 μ g HY1 (left; clear) in 50 μ l PBS at room temperature, and (2) 100 μ g of CpG + 100 μ g HY2 (right; turbid) in 50 μ l PBS at room temperature. The cloudier mixture on the right indicates that a greater amount of precipitate is formed by the mixture of CpG and HY2 polypeptide. Precipitation occurred immediately upon mixing.

FIG. 3 is an example of primary ELISPOT assay results. The KCSRNR CpG-interacting amino acid sequence increased the immunogenicity of the HY1 polypeptide to a greater extent than the RKKRRQ sequence. The wells shown include 4 x 10⁵ CD8⁺ CTLs as responders, and RMA-S stimulators pulsed with polypeptide. The graph indicates frequency of activated CD8⁺ T cells in response to polypeptide stimulation.

FIG. 4 is an example of primary ELISPOT assay results. The ACSANA-HY polypeptide demonstrated the same level of immunogenicity as the KCSRNR-HY1 polypeptide. The wells shown include 4 x 10⁵ CD8⁺ CTLs as responders, and RMA-S stimulators pulsed with HY1 polypeptide. The graph indicates frequency of activated CD8⁺ T cells in response to polypeptide stimulation.

FIG. 5 is a mechanism for binding of the Cys residue in a polypeptide to the phosphorothiol linkage of synthetic CpG.

FIG. 6 is an example of primary ELISPOT assay results. The substitution of Ala for Cys in the KCSRNR CpG-interacting amino acid sequence of HY1 diminishes increased immunogenicity of the HY1 polypeptide. The wells shown include 4 x 10⁵ CD8⁺ CTLs as

responders and RMA-S stimulators pulsed with HY1 polypeptide. The graph indicates frequency of activated CD8⁺ T cells in response to polypeptide stimulation.

FIG. 7 is an example of primary ELISPOT assay results. The elimination of MPL-AF adjuvant from the priming combination of KCSRNR-HY1 and CpG appeared to increase the efficiency of priming. The wells shown include 2.5×10^5 CD8⁺ CTLs as responders and RMA-S stimulators pulsed with HY1 polypeptide. The graph indicates frequency of activated CD8⁺ T cells in response to polypeptide stimulation.

FIG. 8 is an example of primary ELISPOT assay results. The linkage of KCSRNR CpG-interacting amino acid sequences to two melanoma CTL-activating polypeptides (AAGIGILTV (MelanA) and KTWQYWQV (gp100)) and the immunodominant influenza polypeptide (GILGFVFT) resulted in increased priming of HLA-A2 transgenics when mixed with CpG +MPL-AF in comparison to their respective native polypeptides. The wells shown include 3×10^5 CD8⁺ CTLs as responders with T2 stimulators pulsed with polypeptide. The graph indicates frequency of activated CD8⁺ T cells in response to polypeptide stimulation.

FIG. 9 is a graphical representation of absorption data. Formation of a precipitate results in decreased absorbance. The data indicate that positively charged residues in the CpG-interacting amino acid sequences of HY1 mediate virtually complete precipitation of CpG with concentrations used for *in vivo* priming.

DETAILED DESCRIPTION

The invention is based, at least in part, on the discovery that a short, strongly immunogenic polypeptide can efficiently complex with and precipitate a CpG molecule. Attachment of the immunogenic CpG-interacting polypeptide to a weakly immunogenic polypeptide (referred to herein as a “CTL-activating” polypeptide) can precipitate and focus the CpG adjuvant to increase the *in vivo* priming of a cytotoxic T-lymphocyte (CTL) response. The strongly immunogenic polypeptide includes at least one cysteine (Cys) residue and at least one positively charged amino acid residue, and the CpG molecule includes at least one sulfur atom. Fusion of the strongly immunogenic CpG-interacting polypeptide with a CTL-activating polypeptide can produce a bipartite polypeptide of the invention. The amino acid sequence of the CTL-activating polypeptide can be heterologous to the amino acid sequence of the CpG-

interacting polypeptide. The resulting bipartite immunogenic polypeptide can also be called a “primotope.”

The CTL-activating amino acid sequence of the bipartite immunogenic polypeptide can be a polypeptide that binds to MHC Class I molecules. Thus, the bipartite immunogenic polypeptide of the invention can also be known as a CTL-activating polypeptide with enhanced priming potential, or an MHC Class I binding polypeptide with enhanced priming potential. The enhanced priming potential comes from a short CpG-interacting amino acid sequence fused to the polypeptide that binds MHC class I molecules. The short amino acid sequence includes at least one (*e.g.*, 1, 2, 3, or more) positively charged amino acids and at least one Cys residue. At least one positively charged amino acid of the CpG-interacting amino acid sequence can be Arg, Lys, or His. The total length of the CpG-interacting amino acid sequence can be less than about 20 amino acids long (*e.g.*, less than about 15, 12, 10, 8, or 6 amino acids long).

A CpG-interacting amino acid sequence can be added to an antigen of interest in order to increase the immunogenicity of that antigen. The cysteine residues of the sequence can covalently link the CpG-interacting polypeptide (and hence the antigen to which it is attached) to a CpG molecule. The CpG molecule is an immune system stimulant that elicits a strong cell-mediated immune response. These CpG molecules are routinely used as adjuvants in vaccine research, during which they are given in their free form (they are not routinely linked to any other molecules as described in this disclosure). However, CpG molecules are not approved for human use because their systemic administration triggers a toxic shock response (this is one problem that the current disclosure overcomes). The majority of CpG molecules used as adjuvants are synthesized using a phosphorothioate backbone in order to make the oligonucleotides more stable and less sensitive to nucleases. The presence of the sulfur groups in the phosphorothioate backbone of the CpG oligonucleotides allows for the formation of disulfide bonds with the sulfur residue of the cysteines contained in the CpG-interacting amino acid sequence. This disulfide covalent linkage between the CpG-interacting amino acid sequence and the CpG oligonucleotide is the first step in the process of increasing antigen immunogenicity.

The aggregation of several polypeptides-CpG compounds can form a precipitate and result in increased antigen immunogenicity. The positively charged amino acids of the CpG-interacting amino acid sequence can interact with the negatively charged backbone of the CpG oligonucleotides to form the aggregates. The resulting precipitate can perform two functions:

(1) it can increase aggregate (antigen) uptake by antigen presenting cells (the first step in forming an immune response to the antigen) and (2) it can localize the CpG molecules to prevent systemic circulation (and hence toxic shock). The CpG-interacting amino acid sequences can have a periodicity of positively charged amino acids. Because of the helical nature of one or more CpG molecules, the negative charges are oriented in a certain way. In order for the CpG-interacting amino acid sequence to orient the positively charged amino acids into a conformation best able to bind the negative charges of the CpG molecule, single or multiple spacer amino acids can be used. A general orientation can be B-X-B, where B is a positively charged amino acid residue, and X is an amino acid residue. The B residue can be, for example, an arginine or lysine. In one embodiment, the CpG-interacting amino acid sequence can be B-X-B-X-B, B-X-X-B-X-B, B-X-X-B-X-X-B, and the like.

The development of immunotherapeutic methods can provide alternative treatments for human tumors that resist standard treatment methods including chemotherapy and radiation therapy. Tumor-specific cytotoxic T lymphocytes (CTLs) have been a principal focus for immunotherapy because of their exquisite specificity in lysing tumor cells with limited collateral damage. The objective of such immunotherapy is the priming for expansion of CTLs that are specific for tumor-specific polypeptides presented by products of class I genes of the major histocompatibility complex.

Class I-binding polypeptides that include multiple positively charged amino acids and at least one cysteine residue exhibit the ability to complex with and precipitate CpG molecules, and the addition of these amino acids to weakly immunogenic polypeptides increases immunogenicity when combined with CpG molecules for immunization. This increased immunogenicity is accompanied by a decrease in the systemic effects of CpG molecules suggesting that co-precipitated polypeptide and CpG molecules provide the basis for development of vaccines with increased immunogenicity and half-life with reduced adjuvant-mediated toxicity. The simultaneous delivery of two components simplifies the administration of vaccine and expectedly provides protection from degradation for each component. The relative ease of production of these vaccines would enable custom designing of vaccines for individual tumor types for timely administration.

Bipartite Immunogenic Polypeptides The bipartite immunogenic polypeptides of the invention can consist of a CpG-interacting amino acid sequence (*e.g.*, a CpG-interacting amino

acid “tail”) and a CTL-activating sequence, which can be heterologous to the CpG-interacting amino acid sequence. The CpG-interacting amino acid sequence can be located at any position in the bipartite immunogenic polypeptide, such as at, or near, the N- or C-terminus, or in about the middle of the polypeptide. The CTL-activating sequence can be an MHC Class I binding polypeptide. An immunogenic polypeptide of the invention is the shortest polypeptide that can be efficiently processed and presented by APCs, bound by class I molecules, and recognized by specific CTLs *in vivo*. The total length of the bipartite immunogenic polypeptide can be less than about 100 amino acids long, preferably less than about 50 amino acids long (*e.g.*, less than about 40, 35, 30, 25, 20, or 15 amino acids long).

Fully processed polypeptides are those that optimally bind to MHC molecules for recognition by effector T cells. Without wishing to be bound by theory, the positively charged CpG-interacting amino acid sequence can provide the necessary characteristics that allow the immunogenic polypeptide of the invention to be taken up by APCs.

CpG-Interacting Amino Acid Sequence The CpG-interacting amino acid sequence can complex with and concentrate the adjuvant activity of CpG motifs for activation of localized APCs.

The number of positive amino acids in the CpG-interacting amino acid sequence can be the minimal number required for complexing with CpG (*e.g.*, 1, 2, 3, or more positive amino acids); an excess of positively charged residues may block T cell activation and expansion in a short term scenario, but can be effective in stimulating T cell activation over a long term period. This inhibition may be caused by a concentrated precipitation of CpG that sequesters both the polypeptide and CpG in an inactive complex. The Cys and positively charged amino acids can occur at any position within the CpG-interacting amino acid sequence, and the other amino acids can be any amino acid, but preferably the positively charged amino acids are spaced at regular intervals throughout the sequence. For example, a positively charged amino acid can be positioned at every other, every third, or every fourth amino acid position. It is not necessary that the placement of the positive amino acid residues has perfect periodicity. The CpG-interacting amino acid sequence can be, for example, any CpG-interacting amino acid sequence described herein. The CpG-interacting amino acid sequence can be, for example, KCSRNR.

While not wishing to be bound by theory, the cysteine residues of the CpG-interacting amino acid sequence can covalently link the CpG-interacting amino acid sequence (and so also the CTL-activating amino acid sequence to which it is attached) to a CpG molecule.

CTL-Activating Amino Acid Sequence A “CTL-activating” polypeptide is defined by a CTL-activating amino acid sequence. A polypeptide can be categorized as a CTL-activating polypeptide if administration to a mammal, such as a mouse, or a human, results in increased levels of activated CTLs. The level of activated CTLs can be monitored by a variety of methods known in the art, including, but not limited to, ELISA and ELISPOT assays.

Polypeptides that are rich in disulfide bonds (such as IgG) may not require a heterologous CpG-interacting sequence, but instead can themselves bind enough CpG molecules to elicit a heightened immune response. These highly antigenic polypeptides can have at least four cysteine residues (e.g., 5, 10, 15, 20, 25, or 30 cysteines) per 100 contiguous amino acids. The polypeptide can also be rich in disulfide bonds. For example, the polypeptide can contain at least two disulfide bonds (e.g., 3, 4, 5, 6, 7, 8, 9, 10, or 15 disulfide bonds) when it is folded in its natural state. The antigenic polypeptide can be treated with a denaturant, such as urea, guanidine chloride, guanidine thiocyanate GdmSCN, or heat and beta-mercaptoethanol, to break the disulfide bonds, and then the denatured polypeptide can be mixed with CpG molecules and a precipitate allowed to form. The resulting mixture can be used as an immunotherapeutic formulation as described herein.

CpG molecule A CpG molecule, as described herein, is an oligonucleotide that contains at least one unmethylated cytidine-guanosine dinucleotide. CpG molecules can be about 15-25 nucleotides long, preferably about 18-20 nucleotides long. The oligonucleotide can include at least one CpG consensus motif of RRCpGY (R is purine and Y is pyrimidine). The CpG molecules can include a backbone of at least one phosphorothioate linkage, and preferably, the backbone of the entire CpG molecule consists of phosphorothioate linkages. The side chains of a phosphorothioate backbone contain at least one or more sulfur atoms in place of oxygen, and a phosphorothioate backbone can yield a longer half life, increased level of activity, and subtle changes in the specificity of activity (Kreig, *Annu. Rev. Immunol.* 20:709, 2002) can an oligonucleotide backbone that does not include a sulfur atom. While not being bound by theory, the sulfur atoms of the phosphorothioate backbone can form disulfide linkages with the Cys

residue(s) of the CpG-interacting amino acid sequence, which can enhance the immunogenic response.

Any CpG molecule, or any DNA molecule with a phosphorothioate linkage for coupling through disulfide bonds, can be used in the compositions and methods described herein. For example, the CpG molecule 1826 (5'-TCC A TG ACG TTC CTG ACG TT-3'), specific for mouse TLR (Davis *et al. J. Immunol.* 160:870, 1998) can be used as described. See also CpG molecules described in Lingnau *et al. (Vaccine* 20:3498-3508, 2002), for example.

Immunotherapeutic Formulations The compositions and methods described herein can be used in the form of vaccinations, to treat or prevent a disease or disorder, such as cancer. An exemplary immunotherapeutic composition contains a bipartite immunogenic polypeptide and CpG molecules in an oil emulsion, such as Incomplete Freund's Adjuvant. Optionally, an immunotherapeutic composition can include MPL-AF (monophosphoryl Lipid A adjuvant (MPL) mixed with dipalmitoyl phosphatidyl choline (DPPC)).

An immunotherapeutic composition described herein can contain a heterologous mixture of bipartite immunogenic polypeptides. For example, the mixture can contain polypeptides with distinct CTL-activating and CpG-interacting amino acid sequences, or one species of CTL-activating sequences can be coupled to a variety of different CpG-interacting amino acid sequences. The use of various CpG-interacting amino acid sequences can provide a collection of bipartite immunogenic polypeptides with varying stability and varying CTL activation capabilities. For example, and without wishing to be bound by theory, shorter CpG-interacting amino acid sequences containing fewer or one cysteine residue can activate CTLs in the shorter term, providing an immediate priming effect, while longer CpG-interacting amino acid sequences with multiple cysteine residues, or greater numbers of positively charged residues, can provide longer-term priming activity.

As used herein, a vaccine is a composition that provides protection against a viral infection, cancer or other disorder or treatment for a viral infection, cancer or other disorder. Protection against a viral infection, cancer or other disorder will either completely prevent infection or the tumor or other disorder, or will reduce the severity or duration of infection, tumor or other disorder if subsequently infected or afflicted with the disorder. Treatment will cause an amelioration in one or more symptoms or a decrease in severity or duration. For purposes herein, a vaccine results from administration of the bipartite immunogenic polypeptides

and CpG molecules described herein. As used herein, amelioration of the symptoms of a particular disorder by administration of a particular composition refers to any lessening, whether permanent or temporary, lasting or transient that can be attributed to or associated with administration of the composition.

Administration of the immunotherapeutic compositions described herein can activate Langerhans cells and antigen presenting cells (APCs), each of which is capable of presenting the antigenic polypeptide to CTLs, thereby activating the CTLs. The immunotherapeutic compositions can also be administered with a second therapeutic agent or regimen. For example, an immunotherapeutic agent can be administered to a patient who also receives chemotherapy or radiation therapy, such as for a cancer.

An immunotherapeutic composition described herein can be provided in solution, such as in sterile water or a buffer, or the composition can be packaged in a lyophilized form. Kits containing the compositions can include solubilizing reagents, such as sterile water or buffers and/or reagents for diluting a solution and/or otherwise adjusting the properties of a solution in preparation for an intended use. A kit can also include informational material; informational material can be descriptive, instructional, marketing or other material that relates to the methods described herein and/or the use of the immunotherapeutic compositions for the methods described herein.

The informational material of the kits is not limited in its form. In many cases, the informational material is provided in printed matter, such as in printed text, drawings, and/or photographs. The instructional material can be in the form of a label or printed sheet. However, the informational material can also be provided in other formats, such as Braille, computer readable material, video recording, or audio recording. The informational material can include contact information, such as a physical address, email address, website, or telephone number, where a user of the kit can obtain substantive information about an immunotherapeutic composition and/or its use in the methods described herein. Of course, the informational material can also be provided in any combination of formats.

The compositions can be packaged in a variety of suitable containers. For example, a composition can be contained in a bottle, vial, or syringe, composed of a material such as glass or plastic. Optionally, the compositions can be packaged in individual dosage form, such as in

ampoules, syringes, or blister packs. Containers can be air tight and/or waterproof, and can be labeled for use, such as for a vaccine, or to stimulate a CTL response, or to treat a cancer.

Effective Dose The compositions described herein can be administered on multiple occasions and at varying concentrations.

Toxicity and therapeutic efficacy of the compositions disclosed herein (*e.g.*, immunotherapeutic compositions) can be determined by standard pharmaceutical procedures, using either cells in culture or experimental animals to determine the LD₅₀ (the dose lethal to 50% of the population) and the ED₅₀ (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and can be expressed as the ratio LD₅₀/ED₅₀. Polypeptides or other compounds that exhibit large therapeutic indices are preferred.

Data obtained from the cell culture assays and further animal studies can be used in formulating a range of dosage for use in humans. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED₅₀ with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For any composition used in the methods described herein, the therapeutically effective dose can be estimated initially from cell culture assays. A dose can be formulated in animal models to achieve a circulating plasma concentration range that includes the IC₅₀ (that is, the concentration of the immunogenic polypeptides and CpG molecules (free and complexed) which achieves a half-maximal inhibition of symptoms, *e.g.*, treatment of a tumor and/or CTL-activation) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. The amount of bipartite immunogenic polypeptide and CpG molecule in a vaccine dose is selected as an amount that induces an immunoprotective response without significant, adverse side effects in a vaccinee. Such amount can vary depending on the target (*e.g.*, a tumor or systemic vaccination procedure). Generally it is expected that each dose will comprise less than about 500 μ g (*e.g.*, less than about 400, 300, 200, 100, 90, 80, 70, 60, 50, 40, 20 10, 5 or 1 μ g) each of total bipartite immunogenic polypeptide and CpG molecule. The dose can, optionally, comprise an equal molar ratio of the two components. An optimal amount for a particular vaccine can be ascertained by standard studies involving observation of CTL responses, antibody titres, and other responses in subjects.

Following an initial vaccination, subjects may receive a boost in about 4 weeks. The formulations and routes of administration can be tailored to the specific disorder being treated, and for the specific human being treated. For example, the human can have a cancer, such as a leukemia, or a tumor, such as a tumor of the breast, colon, prostate, pancreas or lung.

Generally, administration of an immunotherapeutic agent facilitates an intended purpose for both prophylaxis and treatment without undesirable side effects, such as toxicity, irritation or allergic response. Although individual needs may vary, the determination of optimal ranges for effective amounts of formulations is within the skill of the art. Human doses can readily be extrapolated from animal studies (Katocs *et al.*, Chapter 27 In: Remington's Pharmaceutical Sciences, 18th Ed., Gennaro, ed., Mack Publishing Co., Easton, Pa., 1990). Generally, the dosage required to provide an effective amount of a formulation will vary depending on several factors, including the age, health, physical condition, weight, type and extent of the disease or disorder of the recipient, frequency of treatment, the nature of concurrent therapy, if required, and the nature and scope of the desired effect(s) (Nies *et al.*, Chapter 3, In: Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Ed., Hardman *et al.*, eds., McGraw-Hill, New York, N.Y., 1996).

Screening Methods Various screening methods are also provided herein. One such screening method can be used to identify polypeptides that activate cytotoxic T lymphocytes. The CTL-activating polypeptides can be used in the production of the bipartite immunogenic agents described herein. The methods can include, for example, combining a test polypeptide with a CpG molecule, administering the mixture to a mammal, such as a mouse or a rat, harvesting cytotoxic T lymphocytes from the mammal, and determining whether or not the level of cytotoxic T lymphocytes (*e.g.*, CD8⁺ CTLs) in the mammal is increased.

Other screening methods include procedures to identify a CpG-interacting amino acid sequence, such as for use in a bipartite immunogenic polypeptide. For example, a test amino acid sequence can be contacted with a CpG molecule, and the mixture observed for the formation of a precipitate. The formation of a precipitate indicates that the test amino acid sequence is a CpG-interacting amino acid sequence. The method can further include administering a bipartite immunogenic polypeptide that contains the identified CpG-interacting amino acid sequence. The polypeptide can be administered to a mammal in a formulation with a CpG molecule. By determining whether the polypeptide/CpG molecule composition can activate CTLs in the

mammal, it can be determined that the test CpG-interacting amino acid sequence can function *in vivo* as part of an effective immunotherapeutic reagent.

Sequences identified as CTL-activating sequences or CpG-interacting amino acid sequences can be recorded in a print or machine-readable form. Further, polypeptides containing the identified sequences can be further tested in humans and assayed for an immunogenic response.

The invention is further illustrated by the following examples, which should not be construed as further limiting.

EXAMPLES

Example 1: An immunogenic polypeptide precipitates CpG and enhances activation of CTLs Early experiments in our lab focused on methods required to increase the T cell response to minor histocompatibility antigen (MiHA) polypeptides in mice. Over the past ten years, we have observed a continued decline in the ability of mice to generate CTLs specific for MiHA polypeptides. This decline may be due to the increasingly stringent husbandry procedures in our mouse rooms that have reduced the exposures to pathogens to the point where the immune systems of our mice have no reason to do anything more than maintain homeostasis. Since shifting to primary ELISPOT for quantitation of CTL that produce IFN γ upon stimulation, we have observed that background spots are virtually non-existent in our mice. This is in direct contrast to primary ELISPOT assays with human CTLs, where background activity is ever-present. These observations are consistent with overall decreases in immune activity that must be overcome for effective generation of CTL responses.

Since the defect appeared to be founded in limited exposure to pathogens, we explored the use of bacterial adjuvants to increase CTL responses to MiHA rather than the use of pharmacological methods, *e.g.*, antibody-mediated co-stimulation. We settled on the use of LipidA and a CpG molecule, that bind to TLR-4 and TLR-9, respectively, based on their reported abilities to enhance CTL responses. Lipid A was provided by Corixa Corporation (Seattle, WA) in the form of MPL-AF (MPL adjuvant (monophosphoryl Lipid A) mixed with surfactant-like dipalmitoyl phosphatidyl choline (DPPC)). The CpG molecule used was the 1826 oligonucleotide (TCCA TGAC GTTC CTGA CGTT) that is specific for mouse TLR-9 (Davis *et al.*, *J. Immunol.* 160:870, 1998.); the CpG oligonucleotides were synthesized by the Mayo Clinic

Molecular Biology Core with a phosphorothioate backbone (unless otherwise specified, our use of the term CpG will refer to this synthetic form). This CpG has been successfully used by Celis and co-workers to enhance CTL responses to the OVA polypeptide (SIINFEKL) (Davila *et al.*, *Cancer Res.* 63:3281, 2003). Although this group uses nine subcutaneous (sub cu) injections of CpG to "condition" responder mice before challenge with antigen emulsified in incomplete Freund's adjuvant, we set out to mix CpG, MPL, and antigen for single challenges to avoid the intense, systemic inflammation observed with these repeated treatments with CpG. Preliminary experiments were performed with 10 μ g MPL-AF + 100 μ g CpG mixed with either MiHA-incompatible spleen cells or synthetic MiHA polypeptides (100 μ g) for sub cu injection in the base of the tail.

Frequencies of IFN γ -secreting, MiHA-specific CTLs were estimated by the use of primary ELISPOT assays (Fujihashi *et al.*, *J. Immunol. Meth.* 160:181-189, 1993) that utilized CD8⁺ responders that were enriched by negative selection of other lymphoid populations with MACS CD8⁺ Negative Selection Kits (Miltenyi Biotec, Auburn, CA). Stimulator cells were (1) irradiated allogeneic spleen cells and (2) irradiated syngeneic spleen cells and RMA-S cells pulsed with titrated concentrations of MiHA polypeptides. Responders and stimulators were cultured in anti-IFN γ capture antibody-coated ELISPOT plates for 48 hr after which biotinylated anti-IFN γ detection antibodies were added followed by streptavidin-conjugated HRP and AEC substrate. Spots were counted by first obtaining digitized images of the wells (performed by C.T.L. Analyzers, Cleveland, OH) and then analyzing these images with Immunospot software purchased from C.T.L. Analyzers.

FIG. 1 illustrates that the HY2 polypeptide primes for a stronger response than either the HY1 or H60 polypeptides. B6 females were primed sub cu with 100 μ g polypeptide +10 μ g MPL-AF + 100 μ g CpG. After 10 days, spleens were removed and CD8⁺ CTLs were purified and mixed with RMA-S cells pulsed with the respective polypeptides in a primary ELISPOT assay. Stimulation with RMA-S cells alone resulted in no detectable response.

The combination of MPL-AF + CpG with MiHA incompatible spleen cells resulted in the activation and expansion of CTLs specific for single and multiple MiHA; frequencies in spleens and draining lymph nodes at 10 days post-challenge generally exceeded about 0.1% of CD8⁺ T cells. Furthermore, this adjuvant combination with admixed polypeptide strongly stimulated the generation of CTLs specific for a single HY polypeptide and the immunodominant H60

polypeptide (Malarkannan *et al.*, *J. Immunol.* 161:3501, 1998). The most immunogenic polypeptide, based on spot frequency, was the HY2 polypeptide (KCSRNRQYL) (FIG 1) even though HY antigens have been shown to be subdominant to immunodominant MiHA, including H60 (LTFNYRNL) (Malarkannan *et al.*, *J. Immunol.* 161:3501, 1998). However, a second HY polypeptide (HY1: WMHHNMDLI) was weakly immunogenic in these early studies (FIG 1).

The HY2 polypeptide was initially identified as the target of CTL clones isolated by von Boehmer's and Matzinger's groups (Kirberg *et al.*, *Eur. J. Immunol.* 23:1963, 1993), and the HY1 polypeptide was identified as the target of a CTL selected by Roopenian's group (Scott *et al.*, *Nature* 376:695, 1995). The previously established ranking of H60>HY2>HY1 changed to a ranking of HY2>H60>>HY1 for adjuvant-supplemented, polypeptide-based priming. The HY2 polypeptide was distinguished from all of the other test polypeptides (HY1, H60, and several others) by the formation of precipitates when MPL + CpG were mixed with HY2. The precipitations only required HY2 and CpG (FIG. 2). The HY2 amino acid sequence was examined for characteristics that could promote increased immunogenicity and complexing with the CpG molecule. We tested a panel of polypeptides, some of which did not precipitate upon the addition of CpG, and found that if positively charged amino acids were added to these non-precipitating polypeptides, they now formed precipitates with CpG.

We hypothesized that (1) the formation of precipitates is due to ionic bonds between the positively charged residues in HY2 and the negative charges on CpG molecules and (2) this precipitation enhances stimulation of CTLs. To test these hypotheses, we synthesized two variants of HY1, in which KCSRNR- and RKKRRQ- sequences were added to the amino termini. The KCSRNR sequence was derived from HY2 and the RKKRRQ sequence was derived from the active HIV TAT polypeptide (keeping the length of the CpG-interacting amino acid sequence at six amino acids) (Vives *et al.*, *J. Biol. Chem.* 272:16010, 1997). The two bipartite polypeptides (but not native HY1) precipitated CpG, supporting our first hypothesis. When mixed and injected with CpG + MPL, the HY1 polypeptide fused to the KCSRNR amino acid sequence strikingly increased the frequency of HY1-specific CTLs (FIG. 3). However, the RKKRRQ CpG-interacting amino acid sequence had only a limited effect on immunogenicity. It should be noted that ELISPOT assays were performed with both syngeneic male and native polypeptide-pulsed RMA-S cells as stimulators.

With regard to the RKKRRQ-containing polypeptides, we have also observed that the complete, active HIV TAT polypeptide used in Trojan constructs (Lu *et al.*, *J. Immunol.* 166:7063, 2001) intensely precipitates CpG to the degree that it is difficult to inject, and it inhibits the initial adjuvant activity of CpG in short-term functional assays. Too many positive charges can block T cell activation and expansion. This is consistent with the observation that poly-Arg (60 residues) can rapidly precipitate CpG (Lingnau *et al.*, *Vaccine* 20:3498, 2002); such precipitates can be deposited in tissue and have very long life-spans *in vivo* as evidenced by the ability of these precipitates with associated immunogenic polypeptides to continue priming for at least 372 days (Lingnau *et al.*, *Vaccine* 20:3498, 2002). The potential for selectively and strongly precipitating both immunogenic polypeptides and CpG provides the means to stimulate long-term and durable CTL responses.

Example 2: A cysteine residue is important for increased immunogenicity. To examine the role of Arg/Lys residues in the KCSRNR CpG-interacting amino acid sequence of the HY1 bipartite polypeptide, we substituted Ala residues for the three positively charged residues. The resulting ACSANA-HY1 polypeptide was mixed with CpG and MPL for standard immunization of B6 female mice. The first result of this experiment was the reduced precipitation of CpG with the Ala-substituted polypeptide relative to the KCSRNR-HY1 bipartite polypeptide, although a relatively fine precipitate could still be observed. The ACSANA-HY1 polypeptide did not lose the ability to stimulate expansion of CTLs relative to KCSRNR-HY1 (FIG. 4) with frequencies in splenic CD8⁺ CTLs of 0.033% versus 0.021%. This result can be explained by the presence of sulfur in the backbone of the CpG molecule, which provides the opportunity for covalent, disulfide bonding with the Cys residue of the KCSRNR and ACSANA CpG-interacting amino acid sequence (FIG. 5). Thus multiple bipartite polypeptides can bind to a single CpG molecule.

We synthesized a KASRNR-HY1 immunogenic polypeptide for comparison with the KCSRNR-HY1 and ACSANA-HY1 immunogenic polypeptides for priming of HY1-specific CTLs. Precipitation of CpG was only obtained with the KCSRNR and KASRNR amino acid sequences, pointing toward the importance of the positively charged residues in precipitating CpG. The results of the IFN γ ELISPOT assay of splenic CD8⁺ CTLs are presented in FIG. 6 and demonstrate the importance of the Cys residue for generation of HY1-specific CTLs. The highest frequencies of HY1-specific CTLs were obtained with the KCSRNR and ACSANA

amino acid sequences (0.017% and 0.029%, respectively). The lowest frequency was observed with the KASRNR amino acid sequence (0.003%). These results indicate that the Cys residue is important for maximal and more rapid priming. Also, while positively charged amino acids are required for more rapid precipitation of CpG, their presence cannot overcome the lack of a Cys residue in driving stimulation of an initial, HY1-specific CTL response. This result is consistent with the observation that bipartite polypeptides containing multiple positively charged amino acids (RKKRRQ) from HIV TAT cannot increase CTL frequencies despite their ability to precipitate CpG. These results indicate that a Cys residue and positively charged amino acids can be attached to immunogenic class I-binding polypeptides to promote complexing with CpG molecules and to enhance activation and expansion of CTLs.

Example 3: MPL-AF is not required for increased immunogenicity by an immunogenic polypeptide. We investigated the possibility that MPL-AF is dispensable for MiHA polypeptides that are capable of efficiently precipitating CpG. B6 female mice were primed with the KCSRNR-HY1 immunogenic polypeptide + CpG (in our standard concentrations) with or without MPL-AF. The results of the ELISPOT assay for IFN γ -secreting CTLs demonstrated that the inclusion of MPL-AF in the priming mixtures did not increase the efficiency of stimulation of HY1-specific CTLs and that CpG was sufficient for priming with KCSRNR-HY1 (FIG. 7). In fact, the elimination of MPL-AF appeared to increase the efficiency of priming with only KCSRNR-HY1 and CpG.

Example 4: An immunogenic polypeptide increased immunogenicity of melanoma polypeptides. To determine if the addition of KCSRNR amino acid sequence could increase the immunogenicity of polypeptides other than HY1 and H60, a series of HLA-A2-binding polypeptides with KCSRNR amino acid sequences was synthesized. The series included five polypeptides from the tyrosinase, gp100, and MelanA proteins that are specifically expressed by melanocytes and melanoma cells. Since these proteins are normally expressed in mice and humans, tolerance must be broken to achieve priming of CTLs. We also included the immunodominant influenza polypeptide (GILGFVFTL) that is a foreign protein for mice and humans. All of these bipartite polypeptides precipitated CpG whereas none of the native polypeptides precipitated CpG. Recipient mice were HLA-A2 transgenic mice that were selected

on the B6 background (Le *et al.*, *J. Immunol.* 142:1366, 1989). Although these mice expressed HLA-A2 molecules on the cell surface with densities comparable to H2Db molecules, the frequency of influenza-specific CTLs that were restricted by HLA-A2 was drastically reduced in comparison to the frequency of influenza-specific CTLs that were restricted by H2Db (Le *et al.*, *J. Immunol.* 142:1366, 1989). Further, HLA-A2-restricted CTL responses to immunogenic polypeptides has been shown to be reduced in these transgenics (Engelhard *et al.*, *J. Immunol.* 146:1226, 1991) presumably due to the reduced binding of HLA-A2 molecules to mouse b2M and CD8. These mice, obtained from the Jackson Laboratory, had a reduced responsiveness to HLA-A2-restricted polypeptides. HLA-A2 transgenics were primed sub cu with mixtures of 100 μ g of CpG mixed with (1) 100 μ g of native polypeptides and (2) amounts of KCSRNR-containing polypeptide to yield equimolar CpG:peptide ratios. Spleens were harvested 10 days after immunization and CD8⁺ CTLs were purified by CD8⁺ Negative Selection Kits (Miltenyi Biotec, Auburn, CA) for use in primary IFNgamma ELISPOT assays. Stimulators included T2 cells pulsed with titrated concentrations of native melanoma polypeptides. Non-pulsed T2 cells did not stimulate IFNgamma production. The results of this assay demonstrated that the addition of a KCSRNR amino acid sequence resulted in increased priming for the influenza polypeptide and two of the melanoma-specific polypeptides, AAGIGILTV from MelanA and KTWGQYWQV from gp100 (FIG 8). The responses to KCSRNR-containing polypeptides were ~6-10 fold higher than the responses to the respective, natural polypeptides. Thus, with no modification to priming technique, we were able to boost the response of recipient mice with handicapped CTL responses to polypeptides presented by HLA-A2 molecules.

Example 5: An immunogenic bipartite HY1-Polypeptide precipitated CpG. To confirm the presence of CpG in precipitates, HY1 and a series of immunogenic bipartite HY1 polypeptides were mixed with 100 μ g CpG at molar ratios of approximately 7:1. After 15 min incubation at room temperature, the mixtures were centrifuged at 1000 x g for 15 sec. Optical densities (260/280nm) of diluted supernatants were measured after centrifugation to estimate the efficiency of precipitation of CpG (FIG. 9). These results confirmed that the KCSRNR-HY1 and KASRNR-HY1 polypeptides precipitated nearly all of the CpG in solution; the natural HY1 polypeptide precipitated ~30% of the CpG. These results support the hypothesis that the positively charged amino acids are important for precipitation of CpG and indicate that these

concentrations of bipartite polypeptide and CpG result in the virtually complete conversion of free CpG to precipitated CpG.

Example 6: Immunogenic polypeptide and CpG increased the efficiency of polypeptide absorption by Langerhans cells. The methods described herein can result in the direct precipitation of CpG by a bipartite, immunogenic, class I-binding polypeptide. The direct participation of both molecules in precipitation ensures that both will be present for the duration of the precipitate and its deposit *in vivo*. Antigen-presenting cells (APCs) that take up the precipitate also receive CpG molecules for activation and class I-binding polypeptides for presentation to and recognition by CTLs. To test the uptake of the precipitate by APCs, KCSRNR-HY1 and the HY1 polypeptide were stained with Alexa 488, an amine-reactive dye, according to the manufacturer's protocol (Molecular Probes, Eugene, OR). CpG molecules were stained with Texas Red maleimide through the use of a 5'EndTag Nucleic Acid Labeling System that utilizes T4 polynucleotide kinase (Vector Laboratories, Burlingame, CA). B10 mice were injected in the ears with a mixture of Alexa 488-polypeptide (10 µg/ear) and Texas Red-CpG (10ug/ear). Ears were injected with (A) KCSRNR-HY1 + CpG, or (B) HY1 + CpG. Ears were harvested at 12 hr, which is a time at which Langerhans cells (LCs) have been shown to have been activated by local CpG injections (31). Ears were split and LCs extracted by gentle treatment with 0.25% trypsin in Versene. The LC populations were viewed using an Olympus BX51 fluorescent microscope with a triple-pass filter for FITC (Alexa 488) and TRITC (red).

Images of cells revealed that in ears injected with HY1 + CpG, LCs absorbed both HY1 polypeptides and CpG molecules within 12 hr, but these molecules appeared to be concentrated within separate compartments in the LCs. In ears injected with KCSRNR-HY1 + CpG, the polypeptides and oligonucleotides were dispersed together throughout some of the LCs. Other LCs displayed concentrated CpG within restricted compartments as well as dispersed polypeptides on the surface of cells. Thus precipitates of CpG and KCSRNR-HY1 can be taken up together by LCs with the subsequently effective and rapid (in comparison to HY1) transport of the polypeptides to the cell surface.

Example 7: Known antigens have features of immunogenic polypeptides. The HY2 polypeptide, KCSRNRQYL, includes amino acids that are recognized by CTLs, control binding

to H2Db molecules, mediate binding to CpG (Cys), and precipitate CpG (Arg and Lys). The combination of these characteristics can contribute to the relatively high immunogenicity of HY2 when administered with CpG. Further, the use of the first six amino acids (KCSRNR) of a bipartite HY1 and other polypeptides increases their immunogenicity when combined with CpG. These observations led us to examine the amino acid sequences of proteins that include a variety of immunogenic polypeptides and search for the presence of “natural immunogenic polypeptides” that include not only the recognition polypeptide but also flanking sequences that include Cys and positively charged residues that can bind to CpG. A precursory examination of known tumor, viral, and minor histocompatibility antigens revealed a remarkable tendency for class I-binding polypeptides to be flanked by multiple Arg and/or Lys residues. Table 1 illustrates such linkage in segments of three tumor-related proteins and one viral-encoded protein (class I-binding polypeptides in bold).

Table 1. Known antigens are flanked by Arg and/or Lys residues.

| <i>Gene</i> | <i>Sequence</i> |
|-------------------|--|
| HER-2/neu | IVSAVVGILLVVVLGVVFGILIKRRQQKIRKYTMRRLLQETELV* |
| MelanA | AAGIGILTVILGVLLIGCWYCRRRNGYR |
| PSA-1 | FLTPKKLQCVDLHVISNDVCAQVHPQKVTKFMLCAGRWTGGK |
| Adenovirus 3 (E3) | LIVIGILILSVILYFIFCRQIPNVHRNSKRR |

*Residues in bold are class I-binding polypeptides; Arg, Cys, and Lys residues are underlined

Arg is selectively and sparsely used in proteins (Dyer, *J. Biol. Education* 5:15, 1971; King and Jukes, *Science* 164:788, 1969), an indication that the presence of Arg residues in flanking regions of class I-binding polypeptides may not be a random occurrence. The observed regions of positively-charged amino acids are either a part of the polypeptides themselves or tend to be located up to 40 amino acids away from the polypeptide. We observed an apparent correlation between these positively charged segments that carry immunogenic polypeptides and genes whose functions depend on the functions of Arg residues. Proteins that functionally depend on Arg residues, such as DNA binding proteins that must cross nuclear membranes and bind to DNA and members of the hydrophobic ABC transporter family, are highly represented as antigen sources. Continued analysis of known antigens further revealed that multiple

immunogenic polypeptides can be found in clusters that share a linkage with a region of positively-charged amino acids. Thus, the membrane transport of one relatively large region has the potential to deliver more than one epitope simultaneously.

OTHER EMBODIMENTS

A number of embodiments of the invention have been described. Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of the invention. Accordingly, other embodiments are within the scope of the following claims.

WHAT IS CLAIMED IS:

1. A composition comprising a polypeptide and a CpG molecule, wherein said polypeptide comprises a cytotoxic T lymphocyte-activating amino acid sequence and a CpG-interacting amino acid sequence, wherein said cytotoxic T lymphocyte-activating amino acid sequence is heterologous to said CpG-interacting amino acid sequence, wherein said CpG-interacting amino acid sequence comprises at least one cysteine residue and at least one positively charged amino acid residue, and wherein said CpG molecule comprises at least one sulfur atom.
2. The composition of claim 1, wherein said CpG-interacting amino acid sequence comprises no more than 15 amino acid residues.
3. The composition of claim 1, wherein said CpG-interacting amino acid sequence comprises no more than 10 amino acid residues.
4. The composition of claim 1, wherein said CpG-interacting amino acid sequence consists essentially of 6 amino acid residues.
5. The composition of claim 1, wherein said CpG-interacting amino acid sequence comprises an B-X-B sequence, wherein B is a positively charged amino acid residue and X is an amino acid residue.
6. The composition of claim 1, wherein said CpG-interacting amino acid sequence comprises an B-X-B-X-B sequence, wherein B is a positively charged amino acid residue and X is an amino acid residue.
7. The composition of claim 1, wherein said CpG-interacting amino acid sequence comprises at least two cysteine residues.

8. The composition of claim 1, wherein said CpG-interacting amino acid sequence comprises at least 4 positively charged amino acid residues.

9. The composition of claim 1, wherein at least one of said at least one cysteine residue of said CpG-interacting amino acid sequence is flanked by positively charged amino acid residues.

10. The composition of claim 9, wherein said CpG-interacting amino acid sequence comprises the sequence set forth in SEQ ID NO:1 (KCSRNR).

11. The composition of claim 1, wherein said CpG-interacting amino acid sequence consists essentially of the sequence set forth in SEQ ID NO:1 (KCSRNR).

12. The composition of claim 1, wherein said at least one positively charged amino acid residue is an arginine.

13. The composition of claim 1, wherein said at least one positively charged amino acid residue is a lysine.

14. The composition of claim 1, wherein said cytotoxic T lymphocyte-activating amino acid sequence comprises no more than 50 amino acid residues.

15. The composition of claim 1, wherein said cytotoxic T lymphocyte-activating amino acid sequence comprises no more than 25 amino acid residues.

16. The composition of claim 1, wherein said cytotoxic T lymphocyte-activating amino acid sequence comprises no more than 20 amino acid residues.

17. The composition of claim 1, wherein said cytotoxic T lymphocyte-activating amino acid sequence comprises no more than 10 amino acid residues.

18. The composition of claim 1, wherein said polypeptide is less than 50 amino acid residues in length.

19. The composition of claim 1, wherein said polypeptide is less than 40 amino acid residues in length.

20. The composition of claim 1, wherein said polypeptide is less than 30 amino acid residues in length.

21. The composition of claim 1, wherein said polypeptide is less than 20 amino acid residues in length.

22. The composition of claim 1, wherein said CpG molecule comprises a phosphorothioate linkage.

23. The composition of claim 1, wherein said CpG molecule comprises a phosphorothioate backbone.

24. A method for producing a composition having enhanced immunogenicity, said method comprising:

(a) obtaining a polypeptide having a cytotoxic T lymphocyte-activating amino acid sequence and a CpG-interacting amino acid sequence, wherein said cytotoxic T lymphocyte-activating amino acid sequence is heterologous to said CpG-interacting amino acid sequence, and wherein said CpG-interacting amino acid sequence comprises at least one cysteine residue and at least one positively charged amino acid residue; and

(b) contacting said polypeptide to a CpG molecule comprising a sulfur atom to form said composition.

25. A solution comprising a precipitate, wherein said precipitate comprises a polypeptide and a CpG molecule, wherein said polypeptide comprises a cytotoxic T lymphocyte-activating amino acid sequence and a CpG-interacting amino acid sequence,

wherein said cytotoxic T lymphocyte-activating amino acid sequence is heterologous to said CpG-interacting amino acid sequence, wherein said CpG-interacting amino acid sequence comprises at least one cysteine residue and at least one positively charged amino acid residue, and wherein said CpG molecule comprises a sulfur atom.

26. The solution of claim 25, wherein said solution is aqueous.

27. A method for making a solution comprising a precipitate, said method comprising:

(a) obtaining a polypeptide having a cytotoxic T lymphocyte-activating amino acid sequence and a CpG-interacting amino acid sequence, wherein said cytotoxic T lymphocyte-activating amino acid sequence is heterologous to said CpG-interacting amino acid sequence, and wherein said CpG-interacting amino acid sequence comprises at least one cysteine residue and at least one positively charged amino acid residue; and

(b) contacting said polypeptide to a CpG molecule comprising a sulfur atom, wherein said contacting is performed in solution and under conditions wherein said polypeptide and said CpG molecule form a precipitate, thereby forming said solution comprising a precipitate.

28. A method for activating a cytotoxic T lymphocyte within a mammal, said method comprising administering a composition comprising a polypeptide and a CpG molecule to said mammal, wherein said polypeptide comprises a cytotoxic T lymphocyte-activating amino acid sequence and a CpG-interacting amino acid sequence, wherein said cytotoxic T lymphocyte-activating amino acid sequence is heterologous to said CpG-interacting amino acid sequence, wherein said CpG-interacting amino acid sequence comprises at least one cysteine residue and at least one positively charged amino acid residue, and wherein said CpG molecule comprises a sulfur atom.

29. A method of identifying a polypeptide that activates cytotoxic T lymphocytes, said method comprising:

- (a) combining a test polypeptide with a CpG molecule to form a mixture;
- (b) administering said mixture to a mammal;

(c) harvesting cytotoxic T lymphocytes from said mammal; and
(d) determining whether or not the level of CD8⁺ cytotoxic T lymphocytes in said mammal is increased compared to the level of CD8⁺ cytotoxic T lymphocytes in said mammal before step (b), wherein an increase indicates that said test polypeptide is said polypeptide that activates cytotoxic T lymphocytes.

30. The method of claim 29, wherein said cytotoxic T lymphocytes are harvested from the spleen of said mammal.

31. The method of claim 29, wherein said mammal is a mouse.

32. A method of identifying a CpG-interacting amino acid sequence, said method comprising:

(a) contacting a test amino acid sequence with a CpG molecule, wherein said contacting is performed in solution, and

(b) determining whether or not said test amino acid sequence and said CpG molecule form a precipitate, wherein the formation of a precipitate indicates that said test amino acid sequence is said CpG-interacting amino acid sequence.

33. A method of identifying a CpG-interacting amino acid sequence, said method comprising:

(a) administering a polypeptide/CpG molecule mixture to a mammal, wherein said polypeptide comprises a cytotoxic T lymphocyte-activating amino acid sequence and a test amino acid sequence, and

(b) determining whether or not said mixture activates cytotoxic T lymphocyte from said mammal to a level greater than the level of activation that occurs in a control mammal that received a control polypeptide/CpG molecule mixture, wherein the polypeptide of said control polypeptide/CpG molecule mixture lacks said test amino acid sequence, and wherein said greater level of cytotoxic T lymphocyte activation indicates that said test amino acid sequence is said CpG-interacting amino acid sequence.

ABSTRACT

Attachment of the strongly immunogenic polypeptide to a more weakly immunogenic polypeptide can precipitate and focus a CpG adjuvant to increase *in vivo* priming of a cytotoxic T-lymphocyte (CTL) response, and thus increase the immunogenicity of the more weakly immunogenic polypeptide. Accordingly, compositions that include a bipartite immunogenic polypeptide are provided herein. The bipartite polypeptide can include a CpG-interacting amino acid sequence fused to a CTL-activating amino acid sequence that can be heterologous to the CpG-interacting amino acid sequence. Also provided are methods of identifying and using a CpG-interacting amino acid sequence and a bipartite immunogenic polypeptide.

20740975.doc




Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6




Figure 7




Figure 8




Figure 9